至今,GenScript的服务及产品已被Cell, Nature, Science, PNAS等1300多家生物医药类杂志引用近万次,处于行业领先水平。NIH、哈佛、耶鲁、斯坦福、普林斯顿、杜克大学等约400家全球著名机构使用GenScript的基因合成、多肽服务、抗体服务和蛋白服务等成功地发表科研成果,再次证明GenScript 有能力帮助业内科学家Make research easy.

HDAC6 Signaling at Primary Cilia Promotes Proliferation and Restricts Differentiation of Glioma Cells

Cancers (Basel). 2021-04; 
Ping Shi, Lan B Hoang-Minh, Jia Tian, Alice Cheng, Reemsha Basrai, Neil Kalaria, Joseph J Lebowitz, Habibeh Khoshbouei, Loic P Deleyrolle, Matthew R Sarkisian
Products/Services Used Details Operation
Gene Synthesis … To generate ARL13B-deficient S7 or L0 cells, we transfected floating S7 cells in six-well plates with 5 µg/well of pSpCas9 BB-2A-GFP(PX458) vector containing gRNA targeting human ARL13B (Genscript, Piscataway, NJ, USA; Cat #U994KEE060-2/Q385940) using … Get A Quote

摘要

Histone deacetylase 6 (HDAC6) is an emerging therapeutic target that is overexpressed in glioblastoma when compared to other HDACs. HDAC6 catalyzes the deacetylation of alpha-tubulin and mediates the disassembly of primary cilia, a process required for cell cycle progression. HDAC6 inhibition disrupts glioma proliferation, but whether this effect is dependent on tumor cell primary cilia is unknown. We found that HDAC6 inhibitors ACY-1215 (1215) and ACY-738 (738) inhibited the proliferation of multiple patient-derived and mouse glioma cells. While both inhibitors triggered rapid increases in acetylated alpha-tubulin (aaTub) in the cytosol and led to increased frequencies of primary cilia, they unexpectedly reduc... More

关键词

ARL13B, alpha-tubulin, glioblastoma, histone deacetylase 6, primary cilium